{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:30:30Z","timestamp":1761489030547},"reference-count":37,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Health Policy"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.healthpol.2012.10.008","type":"journal-article","created":{"date-parts":[[2012,11,7]],"date-time":"2012-11-07T21:31:19Z","timestamp":1352323879000},"page":"207-215","source":"Crossref","is-referenced-by-count":3,"title":["Utilization and costs of glucose lowering therapies following health technology assessment for the new reimbursement scheme in Sweden"],"prefix":"10.1016","volume":"108","author":[{"given":"Billie","family":"Pettersson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikael","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per","family":"W\u00e4ndell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars-\u00c5ke","family":"Levin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.healthpol.2012.10.008_bib0005","unstructured":"International Diabetes Federation: IDF Diabetes Atlas. 4 edition Brussels: International Diabetes Federation, 2009."},{"key":"10.1016\/j.healthpol.2012.10.008_bib0010","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0195-668X(03)00114-3","article-title":"Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project","volume":"24","author":"Conroy","year":"2003","journal-title":"European Heart Journal"},{"key":"10.1016\/j.healthpol.2012.10.008_bib0015","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.healthpol.2012.10.008_bib0020","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1007\/s00125-006-0297-1","article-title":"Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75)","volume":"49","author":"Stratton","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.healthpol.2012.10.008_bib0025","unstructured":"IDF Clinical Guidelines Task Force: Global guideline for Type 2 diabetes. Brussels: International Diabetes Federation, 2005"},{"key":"10.1016\/j.healthpol.2012.10.008_bib0030","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.healthpol.2012.10.008_bib0035","unstructured":"Medical Products Agency. L\u00e4kemedelsbehandling vid typ 2-diabetes\u2013ny rekommendation;(English translation: Pharmaceutical treatment for type 2 diabetes- new recommendation). http:\/\/www.lakemedelsverket.se\/upload\/halso-och-sjukvard\/behandlingsrekommendationer\/L%c3%a4kemedelsbehandling%20vid%20typ%202-diabetes_rek.pdf; 2010."},{"key":"10.1016\/j.healthpol.2012.10.008_bib0040","unstructured":"National board for health and welfare. Nationella riktlinjer f\u00f6r diabetesv\u00e5rden 2010\u2013St\u00f6d f\u00f6r styrning och ledning (English translation: National guidelines for diabetes care 2010). http:\/\/www.socialstyrelsen.se\/publikationer2010\/2010-2-2\/Sidor\/default.aspx; 2010."},{"key":"10.1016\/j.healthpol.2012.10.008_bib0045","unstructured":"The National Board of Health and Welfare. The Swedish Drug Registry. http:\/\/www.socialstyrelsen.se\/register\/halsodataregister\/lakemedelsregistret; 2011."},{"key":"10.1016\/j.healthpol.2012.10.008_bib0050","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1007\/s00125-006-0331-3","article-title":"Utilisation of antihyperglycaemic drugs in ten European countries: different developments and different levels","volume":"49","author":"Melander","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.healthpol.2012.10.008_bib0055","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00125-007-0593-4","article-title":"Prevalence and incidence rate of diabetes mellitus in a Swedish community during 30 years of follow-up","volume":"50","author":"Jansson","year":"2007","journal-title":"Diabetologia"},{"key":"10.1016\/j.healthpol.2012.10.008_bib0060","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/j.1464-5491.2008.02541.x","article-title":"Prevalence and incidence of Type 2 diabetes and its complications 1996\u20132003 \u2013 estimates from a Swedish population-based study","volume":"25","author":"Ringborg","year":"2008","journal-title":"Diabetic Medicine"},{"key":"10.1016\/j.healthpol.2012.10.008_bib0065","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1007\/s00125-002-0858-x","article-title":"Revealing the cost of Type II diabetes in Europe","volume":"45","author":"Jonsson","year":"2002","journal-title":"Diabetologia"},{"key":"10.1016\/j.healthpol.2012.10.008_bib0070","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/eurpub\/14.1.10","article-title":"The prevalence of known diabetes in eight European countries","volume":"14","author":"Fleming","year":"2004","journal-title":"European Journal of Public Health"},{"key":"10.1016\/j.healthpol.2012.10.008_bib0075","unstructured":"The Dental and Pharmaceutical Benefits Agency (TLV). The review of medicines used for treating diabetes \u2013 A summary. http:\/\/www.tlv.se\/Upload\/Genomgangen\/summary-diabetes.pdf; 2010."},{"key":"10.1016\/j.healthpol.2012.10.008_bib0080","unstructured":"The Dental and Pharmaceutical Benefits Agency (TLV). The Pharmaceutical reviews. http:\/\/www.tlv.se\/in-english-old\/in-english\/; 2011."},{"key":"10.1016\/j.healthpol.2012.10.008_bib0085","unstructured":"Sveriges Riksbank Exchange rates. http:\/\/www.riksbank.com\/templates\/Page.aspx?id=17182; 2011."},{"key":"10.1016\/j.healthpol.2012.10.008_bib0090","unstructured":"The NEPI Foundation \u2013 The Swedish Network for Pharmaco-epidemiology. Diabetesmedel \u2013 effekter av Tandv\u00e5rds \u2013 och l\u00e4kemedelsf\u00f6rm\u00e5nsverkets genomg\u00e5ng december 2009 (English translation: Diabetes treatments\u2014effects of the TLV review December 2009). http:\/\/www.nepi.net\/res\/dokument\/NEPI-rapport-diabetesmedel-100831.pdf; 2010."},{"key":"10.1016\/j.healthpol.2012.10.008_bib0095","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2165\/00019053-200826070-00001","article-title":"Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe","volume":"26","author":"Wettermark","year":"2008","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.healthpol.2012.10.008_bib0100","series-title":"Reasonable drugs \u2013 making decisions with ambiguous knowledge. The economic research institute","author":"Sj\u00f6gren","year":"2006"},{"key":"10.1016\/j.healthpol.2012.10.008_bib0105","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.healthpol.2009.09.014","article-title":"Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment","volume":"94","author":"Wettermark","year":"2010","journal-title":"Health Policy"},{"key":"10.1016\/j.healthpol.2012.10.008_bib0110","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2010. http:\/\/www.whocc.no\/atc_ddd_publications\/guidelines\/; 2009."},{"key":"10.1016\/j.healthpol.2012.10.008_bib0115","unstructured":"The Dental and Pharmaceutical Benefits Agency (TLV). Reimbursement decision, Levemir. http:\/\/www.tlv.se\/Upload\/Beslut_2007\/BES_070618_levemir.pdf; 2007."},{"issue":"Suppl. 1","key":"10.1016\/j.healthpol.2012.10.008_bib0120","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1093\/fampra\/17.suppl_1.S11","article-title":"Experimental and quasi-experimental designs for evaluating guideline implementation strategies","volume":"17","author":"Grimshaw","year":"2000","journal-title":"Family Practice"},{"key":"10.1016\/j.healthpol.2012.10.008_bib0125","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1365-2710.2002.00430.x","article-title":"Segmented regression analysis of interrupted time series studies in medication use research","volume":"27","author":"Wagner","year":"2002","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"key":"10.1016\/j.healthpol.2012.10.008_bib0130","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/pds.1294","article-title":"The new Swedish Prescribed Drug Register \u2013 opportunities for pharmacoepidemiological research and experience from the first six months","volume":"16","author":"Wettermark","year":"2007","journal-title":"Pharmacoepidemiology and Drug Safety"},{"key":"10.1016\/j.healthpol.2012.10.008_bib0135","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1742-7843.2009.00494.x","article-title":"The Nordic countries as a cohort for pharmacoepidemiological research","volume":"106","author":"Furu","year":"2009","journal-title":"Basic and Clinical Pharmacology and Toxicology"},{"key":"10.1016\/j.healthpol.2012.10.008_bib0140","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1007\/s00125-009-1418-4","article-title":"Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study","volume":"52","author":"Hemkens","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.healthpol.2012.10.008_bib0145","unstructured":"European Medicines Agency. European Medicines Agency update on ongoing benefit-risk review of Avandia, Avandamet and Avaglim. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2010\/07\/news_detail_001062.jsp&murl=menus\/news_and_events\/news_and_events.jsp&mid=WC0b01ac058004d5c1&jsenabled=true; 2010."},{"key":"10.1016\/j.healthpol.2012.10.008_bib0150","unstructured":"The Danish association of the pharmaceutical industry. Pricing and reimbursement in Denmark. http:\/\/parno1.ipapercms.dk\/LIF\/Notater\/PricingandreimbursementinDenmark\/; 2007."},{"key":"10.1016\/j.healthpol.2012.10.008_bib0155","series-title":"Andersson Swedish Pharmaceutical Benefit Reforms \u2013 analyses of implementation, pharmaceutical sales patterns and expenditures. Department of Public health and Community Medicine","year":"2006"},{"key":"10.1016\/j.healthpol.2012.10.008_bib0160","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1503\/cmaj.081180","article-title":"Cost-effectiveness of insulin analogues for diabetes mellitus","volume":"180","author":"Cameron","year":"2009","journal-title":"Canadian Medical Association Journal"},{"key":"10.1016\/j.healthpol.2012.10.008_bib0165","series-title":"Long-acting insulin analogues for diabetes mellitus: metaanalysis of clinical outcomes and assessment of cost-effectiveness technology Report number 92","author":"Tran","year":"2007"},{"key":"10.1016\/j.healthpol.2012.10.008_bib0170","series-title":"Assessing evidence for nursing practice","author":"Polit","year":"2008"},{"key":"10.1016\/j.healthpol.2012.10.008_bib0175","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/BF03256147","article-title":"Soft regulations in pharmaceutical policy making: an overview of current approaches and their consequences","volume":"7","author":"Wettermark","year":"2009","journal-title":"Applied Health Economics and Health Policy"},{"key":"10.1016\/j.healthpol.2012.10.008_bib0180","article-title":"Utilization and costs of lipid modifying therapies following health technology assessment for the new reimbursement scheme in Sweden","author":"Pettersson","year":"2011","journal-title":"Health Policy"},{"key":"10.1016\/j.healthpol.2012.10.008_bib0185","unstructured":"The Dental and Pharmaceutical Benefits Agency (TLV). The review of medicines for treating lipid disorders. http:\/\/www.tlv.se\/Upload\/Genomgangen\/review-lipid-disorder.pdf; 2009."}],"container-title":["Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168851012002898?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168851012002898?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,21]],"date-time":"2018-10-21T11:59:11Z","timestamp":1540123151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168851012002898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":37,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S0168851012002898"],"URL":"https:\/\/doi.org\/10.1016\/j.healthpol.2012.10.008","relation":{},"ISSN":["0168-8510"],"issn-type":[{"value":"0168-8510","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}